NASDAQ: ACBAurora Cannabis Inc Stock
$4.75+0.16 (+3.49%)
Updated May 8, 2025
ACB Price
$4.75
Fair Value Price
N/A
Market Cap
$260.67M
52 Week Low
$3.42
52 Week High
$8.14
P/E
-1.58x
P/B
0.66x
P/S
0.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$274.44M
Earnings
-$15.26M
Gross Margin
61.5%
Operating Margin
-1.71%
Profit Margin
-5.6%
Debt to Equity
0.44
Operating Cash Flow
-$14M
Beta
1.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACB Overview
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ACB
Ranked#28 of 60
Ranked#28 of 60
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.25 | A | |
| $4.50 | A | |
| $7.46 | A |
Be the first to know about important ACB news, forecast changes, insider trades & much more!
ACB News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACB is good value based on its book value relative to its share price (0.66x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.16x)
P/B vs Industry Valuation
ACB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACB due diligence checks available for Premium users.
Valuation
ACB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.58x
Industry
15.04x
Market
24.22x
ACB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
2.16x
ACB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACB's financial health
Profit margin
Revenue
$61.2M
Net Income
$21.3M
Profit Margin
34.8%
ACB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$601.8M
Liabilities
$176.5M
Debt to equity
0.44
ACB's short-term assets ($343.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACB's short-term assets ($343.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$20.0M
Investing
-$2.2M
Financing
-$3.9M
ACB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACB vs Pharmaceutical Stocks
Aurora Cannabis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.